Interleukin
From Proteopedia
(Difference between revisions)
| Line 53: | Line 53: | ||
*IL-1 β | *IL-1 β | ||
| - | + | **[[2nvh]], [[9ilb]], [[1iob]], [[5i1b]], [[2i1b]], [[4i1b]], [[1i1b]] - hIL-1 β<br /> | |
| - | + | ||
| - | **[[2nvh]], [[9ilb]], [[1iob]], [[5i1b]], [[2i1b]], [[4i1b]], [[1i1b]] - hIL-1 β | + | |
**[[1tp0]], [[1t4q]], [[1too]], [[1twe]], [[1twm]], [[1s0l]], [[1l2h]], [[1hib]], [[21bi]], [[31bi]], [[41bi]] - hIL-1 β (mutant) <BR /> | **[[1tp0]], [[1t4q]], [[1too]], [[1twe]], [[1twm]], [[1s0l]], [[1l2h]], [[1hib]], [[21bi]], [[31bi]], [[41bi]] - hIL-1 β (mutant) <BR /> | ||
**[[6i1b]], [[7i1b]] - hIL-1 β - NMR<BR /> | **[[6i1b]], [[7i1b]] - hIL-1 β - NMR<BR /> | ||
| Line 66: | Line 64: | ||
**[[2kh2]] - hIL-1 β + SCFV - NMR<BR /> | **[[2kh2]] - hIL-1 β + SCFV - NMR<BR /> | ||
**[[1md6]] – mIL-1F5 – mouse<BR /> | **[[1md6]] – mIL-1F5 – mouse<BR /> | ||
| - | **[[2mib]], [[8i1b]] - mIL-1 β | + | **[[2mib]], [[8i1b]] - mIL-1 β<br /> |
| + | **[[2wry]] - cIL-1 β – chicken<BR /> | ||
| + | **[[3nj5]], [[4x3a]], [[4x39]], [[4x38]], [[4x37]] – cIL-1 β (mutant) <BR /> | ||
*IL-2 (T-cell growth factor) | *IL-2 (T-cell growth factor) | ||
| Line 102: | Line 102: | ||
**[[1hul]] – hIL-5<BR /> | **[[1hul]] – hIL-5<BR /> | ||
| - | **[[3b5k]] – mIL-5<br /> | ||
**[[3qt2]] - hIL-5 + IL-5 receptor α (mutant) <BR /> | **[[3qt2]] - hIL-5 + IL-5 receptor α (mutant) <BR /> | ||
**[[3va2]] - hIL-5 + IL-5 receptor α <BR /> | **[[3va2]] - hIL-5 + IL-5 receptor α <BR /> | ||
| + | **[[3b5k]] – mIL-5<br /> | ||
*IL-6 | *IL-6 | ||
**[[1alu]] – hIL-6<BR /> | **[[1alu]] – hIL-6<BR /> | ||
| - | **[[2l3y]] - mIL-6 residues 27-211 - NMR<br /> | ||
**[[1il6]], [[2il6]] – hIL-6 - NMR<BR /> | **[[1il6]], [[2il6]] – hIL-6 - NMR<BR /> | ||
**[[1p9m]] - hIL-6 + IL-6 receptor α and β<br /> | **[[1p9m]] - hIL-6 + IL-6 receptor α and β<br /> | ||
| - | **[[1i16]] – IL-6 + IL-6 receptor β - Herpesvirus 8<br /> | ||
**[[4j4l]] – hIL-6 + internalin B<BR /> | **[[4j4l]] – hIL-6 + internalin B<BR /> | ||
**[[4ni7]], [[4ni9]] – hIL-6 + nucleotide aptamer<BR /> | **[[4ni7]], [[4ni9]] – hIL-6 + nucleotide aptamer<BR /> | ||
**[[4cni]], [[4o9h]] – hIL-6 + antibody<BR /> | **[[4cni]], [[4o9h]] – hIL-6 + antibody<BR /> | ||
| + | **[[2l3y]] - mIL-6 residues 27-211 - NMR<br /> | ||
| + | **[[1i16]] – IL-6 + IL-6 receptor β - Herpesvirus 8<br /> | ||
*IL-7 | *IL-7 | ||
| Line 133: | Line 133: | ||
**[[2h24]], [[1inr]], [[2ilk]], [[1ilk]] – hIL-10<BR /> | **[[2h24]], [[1inr]], [[2ilk]], [[1ilk]] – hIL-10<BR /> | ||
| - | **[[4x51]] – mIL-10<BR /> | ||
**[[1j7v]] – hIL-10 + IL-10 receptor α (mutant) <BR /> | **[[1j7v]] – hIL-10 + IL-10 receptor α (mutant) <BR /> | ||
| - | **[[1y6k]] - hIL-10 residues 19-178 + IL-10 receptor α | + | **[[1y6k]] - hIL-10 residues 19-178 + IL-10 receptor α<br /> |
| + | **[[4x51]] – mIL-10<BR /> | ||
*IL-10 viral | *IL-10 viral | ||
| Line 212: | Line 212: | ||
**[[1ykb]], [[1m4r]] – hIL-22<BR /> | **[[1ykb]], [[1m4r]] – hIL-22<BR /> | ||
| - | **[[4o6k]] – IL-22 – zebra fish<BR /> | ||
**[[3g9v]] - hIL-22 residues 29-179 + IL-22 receptor α2<BR /> | **[[3g9v]] - hIL-22 residues 29-179 + IL-22 receptor α2<BR /> | ||
**[[3dlq]], [[3dgc]] - hIL-22 residues 29-179 (mutant) + IL-22 receptor α1<br /> | **[[3dlq]], [[3dgc]] - hIL-22 residues 29-179 (mutant) + IL-22 receptor α1<br /> | ||
| - | **[[3q1s]] - hIL-22 residues 29-179 (mutant) + antibody | + | **[[3q1s]] - hIL-22 residues 29-179 (mutant) + antibody<br /> |
| + | **[[4o6k]] – IL-22 – zebra fish<BR /> | ||
*IL-23 | *IL-23 | ||
| Line 239: | Line 239: | ||
**[[4dkc]] - hIL-34<br /> | **[[4dkc]] - hIL-34<br /> | ||
| - | **[[4exn]] - mIL-34<br /> | ||
**[[4dkd]] - hIL-34 active core + macrophage colony-stimulating factor 1 receptor<br /> | **[[4dkd]] - hIL-34 active core + macrophage colony-stimulating factor 1 receptor<br /> | ||
| + | **[[4dke]], [[4dkf]] - hIL-34 active core + antibody<br /> | ||
| + | **[[4exn]] - mIL-34<br /> | ||
**[[4exp]] - mIL-34 active core + macrophage colony-stimulating factor 1 receptor<br /> | **[[4exp]] - mIL-34 active core + macrophage colony-stimulating factor 1 receptor<br /> | ||
| - | **[[4dke]], [[4dkf]] - hIL-34 active core + antibody | ||
*IL-36 | *IL-36 | ||
Revision as of 07:52, 3 September 2019
| |||||||||||
3D structures of interleukin
Updated on 03-September-2019
References
- ↑ Dinarello CA. Biology of interleukin 1. FASEB J. 1988 Feb;2(2):108-15. PMID:3277884
- ↑ Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016 Jan;12(1):14-24. doi: 10.1038/nrrheum.2016.166. Epub 2015, Dec 10. PMID:26656658 doi:http://dx.doi.org/10.1038/nrrheum.2016.166
- ↑ Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med. 2002;1(1):19-25. PMID:14720072
- ↑ Shah N, Kammermeier J, Elawad M, Glocker EO. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep. 2012 Oct;12(5):373-9. doi: 10.1007/s11882-012-0286-z. PMID:22890722 doi:http://dx.doi.org/10.1007/s11882-012-0286-z
- ↑ Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23-63. PMID:22428854
- ↑ Eken A, Singh AK, Oukka M. Interleukin 23 in Crohn's disease. Inflamm Bowel Dis. 2014 Mar;20(3):587-95. doi:, 10.1097/01.MIB.0000442014.52661.20. PMID:24481050 doi:http://dx.doi.org/10.1097/01.MIB.0000442014.52661.20
- ↑ Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009 Jun 4;360(23):2426-37. doi: 10.1056/NEJMoa0807865. PMID:19494218 doi:10.1056/NEJMoa0807865
